Product Description: Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. /[2]Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10(4): S44.
CAS Number: 880266-57-9
Molecular Weight: N/A
Compound Purity: 99.52
Research Area: Inflammation/Immunology; Neurological Disease
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
